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West African Ebola Epidemic after One Year —  
Slowing but Not Yet under Control
To the Editor: During the period from early 
June to mid-September 2014, the epidemic of 
Ebola virus disease (EVD) in Guinea, Liberia, and 
Sierra Leone grew exponentially, with national 
doubling times of between 16 and 30 days.1 On 
the basis of case reports through mid-September, 
and assuming no change in the trajectory of the 
epidemic, we predicted a cumulative total of 21,000 
cases in these three countries by November 2.1 In 
fact, the epidemic did change course in Septem-
ber: the increase in case incidence appears to 
have halted in Guinea and Sierra Leone and has 
reversed in Liberia (Fig. 1). Now, 1 year after the 
first case was reported in December 2013,2 we 
report updated epidemiologic findings for the 
three countries that have been most affected, us-
ing data recorded through December 14.
In the 4 weeks preceding December 14, the 
number of confirmed or probable cases of EVD 
ranged from 77 to 154 per week in Guinea, 73 to 
138 in Liberia, and 327 to 537 in Sierra Leone. By 
December 14, a total of 18,625 confirmed, prob-
able, or suspected EVD cases had been reported 
in eight affected countries (the three mentioned 
above, plus Mali, Nigeria, Senegal, Spain, and 
the United States), with 6971 recorded deaths.2 
The true burden of illness and death is certainly 
higher, but the changes in epidemic trends be-
tween August and December are clear (Fig. 1).
National summary statistics do not tell the 
whole story, however; within the affected coun-
tries, the geographic distribution of cases has 
shifted markedly (Fig. S3 and S7 in the Supple-
mentary Appendix, available with the full text of 
this letter at NEJM.org). In Gueckedou, Guinea, 
where the epidemic began, the incidence of EVD 
has decreased from an average of 11 confirmed 
or probable cases per week between March and 
September to 2 cases per week since the begin-
ning of October, whereas the incidence has in-
creased sharply in the neighboring districts of 
Kerouane, Macenta, and N’zerekore. Districts at 
the epicenter in eastern Sierra Leone (Kailahun and 
Kenema) and northern Liberia (Lofa) reported 
an average of 120 cases per week during July and 
August but only 2 per week since the beginning 
of November. EVD has been persistently active in 
Conakry, the capital of Guinea, since March and 
highly active in all three national capitals since 
June. During the period of peak incidence be-
tween August 11 and October 5, Monrovia, Libe-
ria, averaged close to 200 confirmed or probable 
cases per week. In Sierra Leone, the center of ac-
tivity had moved from the east to the west of the 
country by October; by the second week of De-
cember, the rise in case incidence had slowed in 
Freetown, but the case incidence may still not have 
peaked (Freetown is shown as part of Western 
Area in Fig. S6 and S10 in the Supplementary 
Appendix).
Guided by targets for patient isolation and safe 
burial practices set by United Nations Mission for 
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Ebola Emergency Response, control measures have 
been stepped up since October 1.3 By December 14, 
the total number of beds (>2000) in Ebola treat-
ment centers far exceeded the number of patients 
reported each week, though there were substan-
tial gaps in treatment capacity in some areas of 
all three countries — in western Sierra Leone 
(Freetown and Western Area), in the southeastern 
forest area and some northern districts of Guinea 
(Kerouane, N’zerekore, and Siguiri), and in west-
ern Liberia (Grand Cape Mount). The capacity to 
carry out safe burials has more than doubled 
since October 1; approximately 200 burial teams 
were covering all but a small number of districts 
by December 14. And yet, knowing that many 
deaths are still unreported, and with continuing 
resistance to safe burial practices in some areas, 
deaths from EVD still pose a considerable hazard.
With the changes in the incidence of EVD and 
with the scale-up of case isolation and safe burial 
measures, there have been concomitant changes 
in key epidemiologic parameters. The case repro-
duction numbers (Rt ) for all three countries, aver-
aged across all districts, have now fallen to 
values close to 1 (Fig. 1, and Fig. S24 in the 
Supplementary Appendix). The precise reasons for 
these changes are still being investigated. How-
ever, in a comparison of periods before and after 
October 1, the average time from symptom on-
set to hospitalization decreased from 5.3 days to 
4.3 days, which indicates a reduction in oppor-
tunities for transmission in communities (Table 1, 
and Tables S7 and S8 in the Supplementary Ap-
pendix). Further quantitative analysis is expected 
to support strong anecdotal evidence that com-
prehensive measures to interrupt transmission, 
including careful case finding and contact 
tracing, have had an effect — for instance, in 
eastern Sierra Leone (Kenema) and northern 
Liberia (Lofa).
The uneven success of EVD control measures 
to date, in the face of shifting geographic pat-
terns of transmission, illustrates the continuing 
threat posed by the Ebola virus 1 year after the 
start of the epidemic. A total of 625 confirmed 
or probable cases were reported from Guinea, Li-
beria, and Sierra Leone in the first week of De-
cember, a number similar to the average for the 
preceding 10 weeks (667), but these cases are now 
spread over a wider geographic area. The worst 
fears of persistent exponential growth beyond 
September were not realized; nevertheless, Ebola 
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Figure 1. Case Reproduction Numbers and Weekly Incidence in Guinea, Liberia, and Sierra Leone.
Shown are the estimated case reproduction number (Rt) over time (upper panels) and the observed and projected weekly incidence 
(lower panels) of confirmed and probable cases of Ebola virus disease (EVD), according to the date of symptom onset, from the week 
beginning June 30, 2014, until the week beginning January 12, 2015, on the basis of data reported through December 7 for Guinea and 
November 30 for Liberia and Sierra Leone. The projections shown in the lower panels were generated from Rt estimates derived from 
data on case incidence (daily situation reports) for the 7 weeks through December 7 for Guinea and November 30 for Liberia and Sierra 
Leone (the time period delineated by the vertical dotted lines).
An animated map 
with timeline is 
available at 
NEJM.org
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still presents a huge challenge as we move into 
the second year of the epidemic in West Africa.
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Ebola in Freetown Area, Sierra Leone —  
A Case Study of 581 Patients
To the Editor: Schieffelin et al. (Nov. 27 issue)1 
reported on 106 patients with Ebola virus disease 
who were treated in Kenema, Sierra Leone, in May 
and June 2014. Here we report similar data on the 
631 patients with Ebola virus disease, as confirmed 
by polymerase-chain-reaction assay, who were 
admitted to the Ebola treatment center at the 
Hastings Police Training School near Freetown, 
Sierra Leone, on or after September 20, 2014 (the 
date on which the first patients were admitted to 
that center). The 31% case fatality rate at Hast-
ings is lower than the 74% rate reported by 
Schieffelin et al.
As of December 7, 2014, a total of 50 of the 
631 patients with laboratory-confirmed Ebola vi-
rus disease were still inpatients at Hastings, and 
581 had either died or been discharged after 
testing negative for the Ebola virus in follow-up 
laboratory tests. In total, 183 of the 581 patients 
for whom a final disposition is known died, 
representing a case fatality rate of 31.5%; among 
the patients who died, 38 were dead on arrival 
and the other 145 died after admission. We have 
observed a decreasing case fatality rate among 
inpatients at Hastings, from 47.7% among the 
first 151 patients (September 20 to October 13), 
to 31.7% among the next 126 patients with a 
final disposition (October 14 to November 4), to 
23.4% among the next 304 patients (November 5 
to December 7).
The most common symptoms reported at ad-
mission were fatigue, anorexia, fever, vomiting 
and nausea, diarrhea, muscle pain, joint pain, and 
headache. On average, patients were admitted 
3 or 4 days after the onset of symptoms. The 
inpatients who died usually did so within 3 or 
4 days after admission; survivors usually were 
hospitalized for about 2 weeks.
Our current treatment protocol is as follows (for 
additional details, see Table S1 in the Supplemen-
tary Appendix, available with the full text of this 
letter at NEJM.org): For 72 hours after admission, 
all patients receive 1 g of ceftriaxone intravenous-
ly every 12 hours and 500 mg of metronidazole 
intravenously every 8 hours, as well as 500 ml of 
Ringer’s lactate every 8 or 12 hours and 500 ml 
of dextrose saline (5% and 0.9%, respectively) in-
travenously every 8 or 12 hours. All patients also 
receive 10 mg of vitamin K and 160 mg of arte-
mether intramuscularly immediately on admis-
sion, as well as a 20-mg zinc sulfate tablet daily, 
a 400-mg ibuprofen tablet every 12 hours, and 
10 mg of metoclopramide intravenously as need-
ed for nausea or vomiting. After the first 3 days, 
continuing therapy includes a 400-mg metroni-
dazole tablet every 8 hours for 7 days, a 500-mg 
cefuroxime tablet every 12 hours for 5 days, 
an artesunate–lumefantrine combination-therapy 
tablet daily for 3 days, a 400-mg ibuprofen tab-
let every 12 hours, and one capsule of Immuno-
Boost nutrition supplement (Novopharm Formu-
lations) daily. Oral rehydration solution and juice 
drinks are given freely. It is unclear why the case 
fatality rate is decreasing at Hastings. We are 
unable to assess any individual component of 
the treatments we used, since we applied a 
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